Outline Significance Definitions Challenges Next steps.
-
Upload
bryan-henderson -
Category
Documents
-
view
219 -
download
2
Transcript of Outline Significance Definitions Challenges Next steps.
![Page 1: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/1.jpg)
Outline
• Significance
• Definitions
• Challenges
• Next steps
![Page 2: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/2.jpg)
Significance
• Quality of Life
• Safety
• Efficacy/potentially modifiable
![Page 3: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/3.jpg)
Definitions
• What is neurocognition?
• Inter-related levels of investigation
• But need to be clear on what we are measuring
![Page 4: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/4.jpg)
What to measure
• Depth vs breadth
• Inclusion criteria (make the most of each trial)
• Across age/ability; validation
• Multi-center: multiple cultures/languages
• FDA-requirements: clinical vs regulatory significance
![Page 5: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/5.jpg)
Scientific Challenges
• Drug efficacy– Mouse models: translating from mouse to man– Predicting responders– When and how long to treat
• Placebo-controlled, double blind trials needed
• Side effects of drug– Risk/benefits in pediatric population
• Neurocognitive assessments – Dynamic measures within timeframe of trial– Standard battery across trials
![Page 6: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/6.jpg)
Logistical challenges
• IRB and FDA requirements
• Multi-site enrollment for rare disorders
• Broad Infrastructure – Recruitment, Patient safety, Monitoring, Data
management, Data analysis
• Funding
![Page 7: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/7.jpg)
Next Steps - I
• Patient Based Outcome Measures
• In terms of FDA – f/u neuro-onco, epilepsy trials etc.
• Stratify by epilepsy
• Younger age/adults/more severely affected
• Sleep/depression/anxiety
![Page 8: Outline Significance Definitions Challenges Next steps.](https://reader036.fdocuments.in/reader036/viewer/2022082818/56649f0e5503460f94c228a3/html5/thumbnails/8.jpg)
Next Steps - II
• Off-label use
• Education- importance of neurocog clinical trials
• Biomarkers of cognition
• Funding